| Start Date | 12.11.2024 - 16:30 |
| Event End | 12.11.2024 - 17:30 |
| Location | Universität Zürich, Campus Irchel, Departement für Chemie University of Zurich Winterthurerstrasse 190, 8057 Zurich Lecture Hall Y03-G-95 |
The development of theranostic radiopharmaceuticals, particularly for applications in oncology, is a rapidly expanding field with continued commercial growth predicted over the next decade. Microreactor technologies, supramolecular radiochemistry, theranostic radiopharmaceutical design and in vivo multi-radiotracer imaging protocols offer opportunities to drive innovation in this field.
(1) Microfluidics offer a route into efficient dose-on-demand production of radiopharmaceuticals. We have focussed on novel design of key components that are compatible with the small-scale reactions typical of radiopharmaceutical production.
(2) Significant interest has emerged in the use of supramolecular constructs for nuclear imaging. The CageTag platform that we have developed with Paul Lusby (Edinburgh) is a reagentless, rapid and simple method that could allow the development of “off-the-shelf” theranostic kits.
(3) Imaging of the CXCR4 chemokine receptor (along with ACKR3) expression levels in cancers has potential to provide prognostic data or to inform treatment selection. We have targeted CXCR4 using a novel configurationally restricted azamacrocyclic transition metal complexes radiolabelled for both imaging and therapeutic applications with copper-64/copper-67.
(4) The in vivo imaging of multiple radionuclides simultaneously is relevant to combination therapies and stability profiling in radiotracer validation. Data collected from multiple isotope energy peaks with tailored corrections (e g. downscatter) is presented.